DanDi Bioscience
- HOME
-
ABOUT US
-
WORK
-
PR
-
CAREERS
-
CONTACT US
-
ABOUT US
-
WORK
-
PR
-
CAREERS
-
CONTACT US
- HOME
-
ABOUT US
-
WORK
-
PR
-
CAREERS
-
CONTACT US
What’s new?
2023-01-13danbio
Dandibio, Vietnam's Nanogen and joint research on immuno-oncologyhttp://www.biospectator.com/view/news_view.php?varAtcId=9154
This post has been translated from the original article dated 12/10/2019.
Nano-based immune enhancement platform + biosimilar combination research contract
▲Dand Bio Research Center Director Lim Yong-taek (from left), HLB Bio General Manager Jeon Bok-hwan, Park Young-min, Dandi Bio CEO, Shin Dong-min, Nanogen Financial Director, and Nanogen R&D Research Center Director Do Minh Si joint research on cancer immunotherapy on the 18th concluded a contract Provided by Dandi Bio.
Dandi Bioscience announced on the 20th that it had signed a joint research contract for immuno-anticancer drugs with Nanogen Pharmaceutical Biotechnology JSC, a Vietnamese biopharmaceutical company, on the 18th.
The two companies combined Dandibio's nano-based immune enhancement platform (multi-nanodomain vesicle) with a biosimilar immuno-anticancer drug developed by Nanogen to overcome the low response rate to existing immuno-anticancer drugs and enhance and control immune activity. Through this, we plan to conduct research to maximize the treatment effect of existing immuno-anticancer drugs.
In August, Dandi Bio reported in the international journal Nature Communications that it had developed a treatment technology that could overcome the limitations of immune checkpoint inhibitors.
Increasing the anti-cancer immune function of antigen-specific T cells and antigen-presenting cells (cells that present antigens invaded from the outside) that kill cancer cells, and immunosuppressive cells (MDSC, TAM and Treg) and immunosuppressive cytokines ( It is a technology that enhances and regulates immune activity by inducing changes in the microenvironment within the tumor through two mechanisms that inhibit the immunosuppressive function by TGF-beta and IL-10, etc.).
With this contract, Dandi Bio has joint rights with Nanogen in developing, manufacturing, and commercializing the substance. In addition, by establishing a continuous collaboration system with Nanogen, the company plans to prove that its immunostimulant, immune activation enhancement technology, and drug delivery platform technology based on multi-nanodomain vesicles are highly competitive technologies that can be applied to various diseases.
Nanogen is Vietnam's representative biopharmaceutical company that develops, produces and sells prexxxxxscription drugs and protein drugs. Currently, five biosimilar products, including EPO (anemia treatment and anti-cancer supplement) and Interferon alpha, have been approved and are on sale. He also holds a patent.
Reporter Jang Jong-won jjw@bios.co.kr
CopyrightⓒHLB Science. ALL RIGHTS RESERVED